https://www.pharmaradar360.com/article/642f464f4458d798PharmaRadar360en2026-05-06T11:00:00.000ZRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026https://www.pharmaradar360.com/article/c67872f2a44f0cf8PharmaRadar360en2026-05-06T10:59:00.000ZBristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026https://www.pharmaradar360.com/article/c19c55cf7eda6eebPharmaRadar360en2026-05-06T09:26:28.000ZΕγκύκλιος SUNSET CLAUSEhttps://www.pharmaradar360.com/article/77a2c151edb11abfPharmaRadar360en2026-05-06T07:54:27.000ZField Safety Notices: 1 May 2026https://www.pharmaradar360.com/article/53f5a1efeb03e3d4PharmaRadar360en2026-05-06T07:00:23.000ZLa AEMPS inicia su colaboración con la Agencia Africana del Medicamento (AMA)https://www.pharmaradar360.com/article/60a418171ab76943PharmaRadar360en2026-05-06T06:01:19.000ZAvacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026https://www.pharmaradar360.com/article/a06290eac658b8e9PharmaRadar360en2026-05-06T04:21:52.000ZΓενόσημα Φεβρουαρίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/4ad376d2b0cce5b0PharmaRadar360en2026-05-06T01:36:27.000ZResearch Rising Starts with Peoplehttps://www.pharmaradar360.com/article/e0723cdfd19aaf01PharmaRadar360en2026-05-06T01:18:16.000Z1087 2https://www.pharmaradar360.com/article/ddc45c4a1fa73f4dPharmaRadar360en2026-05-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/c0c71cda180ba744PharmaRadar360en2026-05-06T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/f52c4eb9d03b51e1PharmaRadar360en2026-05-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/8fc08c155d2545c5PharmaRadar360en2026-05-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/cd2ac10e4dbce445PharmaRadar360en2026-05-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/e7b9315b7aded3c7PharmaRadar360en2026-05-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/b85c69ec32ce41b4PharmaRadar360en2026-05-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/364f95db367e366bPharmaRadar360en2026-05-06T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/2d54c2d792ec1364PharmaRadar360en2026-05-06T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/b6214ddf6bbdcce0PharmaRadar360en2026-05-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/e24d017fefaac806PharmaRadar360en2026-05-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/65da3096fbc8a30aPharmaRadar360en2026-05-06T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/ae9150f8c2cb778dPharmaRadar360en2026-05-06T00:00:00.000Z6203https://www.pharmaradar360.com/article/084363c1d7d23237PharmaRadar360en2026-05-06T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/a7661dd486fc2c01PharmaRadar360en2026-05-06T00:00:00.000ZUnited Therapeutics Corporation Reports First Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/d5fecfb31fc103d3PharmaRadar360en2026-05-05T22:08:49.000ZComo llegar a la Juntahttps://www.pharmaradar360.com/article/2d799ad658bab939PharmaRadar360en2026-05-05T22:07:49.000ZSolicitudes de información o aclaración solicitadas por los accionistashttps://www.pharmaradar360.com/article/4382f798e5054aefPharmaRadar360en2026-05-05T22:06:56.000ZSolicitud de información mediante comunicación electrónicahttps://www.pharmaradar360.com/article/9accb35989608f83PharmaRadar360en2026-05-05T22:06:08.000ZDelegación de la representación y voto mediante comunicación electrónicahttps://www.pharmaradar360.com/article/c47345cdd4b9bafaPharmaRadar360en2026-05-05T22:05:22.000ZAcceso asistencia telemática Junta General Ordinaria de Accionistas 2026https://www.pharmaradar360.com/article/ef6adc3241c3f5f3PharmaRadar360en2026-05-05T22:04:26.000ZForo electrónico de accionistashttps://www.pharmaradar360.com/article/482eff96a4f53104PharmaRadar360en2026-05-05T22:03:36.000ZModelo de tarjeta de asistencia, delegación y voto a distanciahttps://www.pharmaradar360.com/article/bb3042b5538106aaPharmaRadar360en2026-05-05T22:02:52.000ZNúmero total de acciones y derechos de votohttps://www.pharmaradar360.com/article/f217940abeeb663fPharmaRadar360en2026-05-05T22:02:08.000ZReglas sobre solicitud de información previa a la Junta, representación y voto mediante medios de comunicación a distanciahttps://www.pharmaradar360.com/article/66479637af1b7ca1PharmaRadar360en2026-05-05T22:01:12.000ZInforme sobre la Independencia del Auditor de Cuentas y del Verificador de la información sobre sostenibilidad 2025https://www.pharmaradar360.com/article/34838094db964cbePharmaRadar360en2026-05-05T21:43:11.000ZDiplomado en Farmacología de los Tratamientos de las Enfermedades Infecciosas, Quimioterapéuticos y Vacunas», entre Asociación MÁS QUE FARMACIA y la Junta de Vigilancia de la Profesión Químico Farmacéutica (JVPQF)https://www.pharmaradar360.com/article/8e5db748754f62a4PharmaRadar360en2026-05-05T19:31:22.000ZInterfarma defende proibição de manipulação de medicamentos à base de GLP‑1https://www.pharmaradar360.com/article/f67889780e31d0fdPharmaRadar360en2026-05-05T16:00:09.000ZA New Chapter in a Longstanding Partnership: SCRS Supports David Vulcano’s Transition to ACRP CEOhttps://www.pharmaradar360.com/article/8ae67aaaf9e8f17bPharmaRadar360en2026-05-05T16:00:00.000ZBio Korea 2026: US policy risks shift to execution frameworkhttps://www.pharmaradar360.com/article/204b30d9e12a4bedPharmaRadar360en2026-05-05T16:00:00.000ZWhite House looks to expand MFN pricing for $530B-plus in savingshttps://www.pharmaradar360.com/article/7cd01ca22005d6e6PharmaRadar360en2026-05-05T13:47:52.000ZCORMEDIX THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 14, 2026https://www.pharmaradar360.com/article/4876ea806c7e9156PharmaRadar360en2026-05-05T13:28:23.000ZUn nouveau chapitre pour le Leem avec l’élection de 35 nouveaux administrateurs et une direction générale par intérimhttps://www.pharmaradar360.com/article/1df8ed0788183b50PharmaRadar360en2026-05-05T12:48:11.000ZACRP Names David M. Vulcano as New Chief Executive Officerhttps://www.pharmaradar360.com/article/ecd9834dbe1246ecPharmaRadar360en2026-05-05T12:45:00.000ZMerck Completes Acquisition of Terns Pharmaceuticals, Inc.https://www.pharmaradar360.com/article/128dc3e842feebebPharmaRadar360en2026-05-05T12:05:00.000ZAbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®https://www.pharmaradar360.com/article/13db037a7d2b68dbPharmaRadar360en2026-05-05T11:00:00.000ZRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026https://www.pharmaradar360.com/article/e0253f11bcfbc844PharmaRadar360en2026-05-05T10:45:00.000ZLilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years